The NHERF1-STIM1-Orai1 axis regulates MRGPRX2 responses in mast cells
The NHERF1-STIM1-Orai1 axis regulates MRGPRX2 responses in mast cells
批准号:
10538916
负责人:
Hariharan Subramanian
金额:
$20.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-02-01 至 2024-01-31
关键词:
AblationAdaptor Signaling ProteinAffectAgent 48-80AgonistAllergicAllergic DiseaseAllergic ReactionAnaphylaxisAsthmaBiological AssayCD34 geneCell CompartmentationCell physiologyCellsCellular biologyChronicClinicalCouplesCouplingDataDevelopmentDiseaseEdemaFutureG-Protein-Coupled ReceptorsGeneticGoalsGrantHumanImmuneIn VitroInflammationInflammatoryInterventionMediatingMolecularMusNational Heart, Lung, and Blood InstituteNational Institute of Allergy and Infectious DiseaseOrthologous GenePathogenesisPathologyPathway interactionsPharmaceutical PreparationsPharmacologyPlayProteinsReactionResearchRoleRosaceaSTIM1 geneSignal TransductionTestingTimeLineTissuesUmbilical Cord BloodUnited States Food and Drug AdministrationUnited States National Institutes of HealthUrticariaallergic responsecathelicidincell typechronic inflammatory diseaseclinical applicationcytokinedrug developmentexperimental studyin vivoin vivo Modelinsightknock-downmast cellmouse modelmutantnovelnovel therapeuticsreceptorresponsesensorsodium-hydrogen exchanger regulatory factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Mast cells are tissue resident innate immune cells that have been best characterized for their role in mediating
allergic diseases. A recent development in mast cell research has been the identification and characterization of
a novel G protein coupled receptor, Mas-Related G-Protein-coupled Receptor X2 (MRGPRX2). This receptor
promotes pseudoallergic reaction to U.S. Food and Drug Administration (FDA) approved drugs and chronic
inflammation in diseases such as asthma, rosacea and hives (urticaria). While the role of MRGPRX2 in promoting
allergic reactions has been investigated, the molecular mechanisms utilized by this receptor is poorly understood.
Our data suggests that a Ca2+ sensor protein, stromal interaction molecule 1 (STIM1), which is an essential
component of the store operated Ca2+ entry (SOCE) pathway, regulates MRGPRX2- and MrgprB2- (the mouse
ortholog of the human receptor) induced responses in mast cells. Specifically, silencing the expression of STIM1
or pharmacological targeting of SOCE pathway results in reduced intracellular Ca2+ mobilization, degranulation
and cytokine release following mast cell activation via MRGPRX2/MrgprB2 in vitro. Consistent with this data,
inflammation is also reduced in in vivo mouse models of rosacea and paw edema when the SOCE pathway is
pharmacologically inhibited. This proposal builds up on these observations; the central hypothesis is that STIM1
is a critical regulator of MRGPRX2 responses in mast cells. We will determine the role of STIM1 in regulating
human MRGPRX2 and mouse MrgprB2 response in vitro and in vivo (Aim 1). STIM1 couples to the Orai1
channel to mediate SOCE in several cell types. In Aim 1, we will also test whether the STIM1-Orai1 interaction
regulates mast cells responses following MRGPRX2/MrgprB2 activation. Similar to data obtained with STIM1
knockdown mast cells, silencing the expression of Na+/H+ exchanger regulatory factor (NHERF)1, an adaptor
protein reduced MRGPRX2/MrgprB2-dependent Ca2+ mobilization in vitro and passive systemic anaphylaxis in
vivo. How NHERF1 regulates STIM1 functions and affect intracellular Ca2+ mobilization is currently unknown. In
Aim 2, we will explore the contribution of the NHERF1-STIM1-Orai1 axis in modulating mast cell response via
the MRGPRX2/MrgprB2 receptors. Given the critical role of mast cell MRGPRX2 in causing pseudoallergic
reactions and chronic inflammation in allergic diseases, elucidation of the mechanisms by which STIM1 and
NHERF1 regulates mast cell MRGPRX2-mediated allergic response is of significant scientific and clinical
importance. The successful completion of the proposed studies will likely lead to the identification of potential
targets of the MRGPRX2 pathway that can provide insights into the future development of drugs for not only
pseudoallergic reactions but also other mast cell-mediated inflammatory diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NHERF1 regulates MRGPRX2/MrgprB2 responses in mast cells
-
批准号:10711042
-
项目类别:
-
资助金额:$46.07万
-
财政年份:2023
-
负责人:Hariharan Subramanian
-
依托单位:
A novel role for the adapter molecule NHERF1 in regulating asthma and allergic re
-
批准号:9172283
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2014
-
负责人:Hariharan Subramanian
-
依托单位:
A novel role for the adapter molecule NHERF1 in regulating asthma and allergic re
-
批准号:8617363
-
项目类别:
-
资助金额:$10.81万
-
财政年份:2014
-
负责人:Hariharan Subramanian
-
依托单位: